Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Common Equity (2016 - 2025)

Avanos Medical (AVNS) has disclosed Common Equity for 13 consecutive years, with $778.2 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 6.07% to $778.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $778.2 million through Dec 2025, down 6.07% year-over-year, with the annual reading at $778.2 million for FY2025, 6.07% down from the prior year.
  • Common Equity hit $778.2 million in Q4 2025 for Avanos Medical, roughly flat from $778.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.7 billion in Q2 2024 to a low of -$700.4 million in Q1 2025.
  • Historically, Common Equity has averaged $954.9 million across 5 years, with a median of $1.2 billion in 2021.
  • Biggest five-year swings in Common Equity: skyrocketed 2781.02% in 2021 and later crashed 637.26% in 2025.
  • Year by year, Common Equity stood at $1.3 billion in 2021, then grew by 1.62% to $1.3 billion in 2022, then dropped by 4.25% to $1.2 billion in 2023, then plummeted by 32.99% to $828.5 million in 2024, then dropped by 6.07% to $778.2 million in 2025.
  • Business Quant data shows Common Equity for AVNS at $778.2 million in Q4 2025, $778.0 million in Q3 2025, and -$101.9 million in Q2 2025.